Rolf Engstad - Academia.edu (original) (raw)
Papers by Rolf Engstad
Cette invention concerne l'utilisation de β-(1,3)-glucanes solubles dans l'eau, pratiquem... more Cette invention concerne l'utilisation de β-(1,3)-glucanes solubles dans l'eau, pratiquement exempts de liaisons (1,6), comme agents actifs pour la preparation d'agents therapeutiques pour les soins de peau. Lesdits agents therapeutiques renforcent le systeme immunitaire de la peau, agissent contre la formation des rides et peuvent etre utilises pour lutter contre les pellicules et le psoriasis.
b-Glucans are known for their ability to trigger both protective and damaging immune responses. H... more b-Glucans are known for their ability to trigger both protective and damaging immune responses. Here we have explored the role of the betaglucan receptor Dectin-1 in archetypical models of protective and non-protective immunomodulation induced by beta-glucan rich ligands. In the first model, we explored the role of Dectin-1 in the ability of soluble purified b-glucans to mediate protection against systemic Staphylococcus aureus infection in mice. In the second model, we explored the role of Dectin-1 in zymosan induced multiple organ dysfunction syndrome. In both cases, these b-glucan rich compounds had marked effects in vivo which were unaltered by Dectin-1 deficiency, suggesting that this receptor has a redundant role in these murine models. 2013 Institut Pasteur. Published by Elsevier Masson SAS.
TREATMENT TO BE - (1-6) -glucanase, glycan FROM YEAST CELLS, PARTICULARLY YEAST SACCHAROMYCES FAM... more TREATMENT TO BE - (1-6) -glucanase, glycan FROM YEAST CELLS, PARTICULARLY YEAST SACCHAROMYCES FAMILY AND ESPECIALLY of Saccharomyces cerevisiae, PROVIDES A NEW PRODUCT glucan, SUITABLE FOR USE IN ENHANCING STIMULATION immune systems of the host animal. Further it described solubilization OF SUCH glucan yeast cell, TO EXTEND THEIR USE AS AUXILIARY PRODUCT.
European Journal of Pharmaceutics and Biopharmaceutics, 2021
To relieve the severe economic and social burdens and patient suffering caused by the increasing ... more To relieve the severe economic and social burdens and patient suffering caused by the increasing incidence of chronic wounds, more effective treatments are urgently needed. In this study, we focused on developing a novel sprayable wound dressing with the active ingredient β-1,3/1,6-glucan (βG). Since βG is already available as the active ingredient in a commercial wound healing product provided as a hydrogel in a tube (βG-Gel), the sprayable format should bring clinical benefit by being easily sprayed onto wounds; whilst retaining βG-Gel's physical stability, biological safety and wound healing efficacy. Potentially sprayable βG hydrogels were therefore formulated, based on an experimental design setup. One spray formulation, named βG-Spray, was selected for further investigation, as it showed favorable rheological and spraying properties. The βG-Spray was furthermore found to be stable at room temperature for more than a year, retaining its rheological properties and sprayability. The cytotoxicity of βG-Spray in keratinocytes in vitro, was shown to be promising even at the highest tested concentration of 100 μg/ml. The βG-Spray also displayed favorable fluid affinity characteristics, with a capacity to both donate and absorb close to 10% fluid relative to its own weight. Finally, the βG-Spray was proven comparably effective to the commercial product, βG-Gel, and superior to both the water and the carrier controls (NoβG-Spray), in terms of its ability to promote wound healing in healing-impaired animals. Contraction was found to be the main wound closure mechanism responsible for the improvement seen in the βG-treatment groups (βG-Spray and βG-Gel). In conclusion, the novel sprayable βG formulation, confirmed its potential to expand the clinical use of βG as wound dressing.
Pharmaceutics, 2021
An active wound dressing should address the main goals in wound treatment, which are improved wou... more An active wound dressing should address the main goals in wound treatment, which are improved wound healing and reduced infection rates. We developed novel multifunctional nanofibrous wound dressings with three active ingredients: chloramphenicol (CAM), beta-glucan (βG) and chitosan (CHI), of which βG and CHI are active nanofiber-forming biopolymers isolated from the cell walls of Saccharomyces cerevisiae and from shrimp shells, respectively. To evaluate the effect of each active ingredient on the nanofibers’ morphological features and bioactivity, nanofibers with both βG and CHI, only βG, only CHI and only copolymers, polyethylene oxide (PEO) and hydroxypropylmethylcellulose (HPMC) were fabricated. All four nanofiber formulations were also prepared with 1% CAM. The needle-free NanospiderTM technique allowed for the successful production of defect-free nanofibers containing all three active ingredients. The CAM-containing nanofibers had a burst CAM-release and a high absorption capa...
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2018
The increased prevalence of chronic wounds requires novel treatment options. The aim of this stud... more The increased prevalence of chronic wounds requires novel treatment options. The aim of this study was to develop a beta-glucan (βG)-loaded nanofiber wound dressing. Nanofibers were prepared using the needle-free Nanospider™ technology, an electrospinning method which enables the production of nanofibers at an industrial scale. The βG was selected as active ingredient based on its confirmed wound healing potential in both animals and humans. Hydroxypropyl methylcellulose (HPMC) and polyethylene oxide (PEO) were included as copolymers. Rheological profiles of spinning solutions containing HPMC, PEO, βG, ethanol and water, were optimized. The nanofiber formation was confirmed by Field Emission Scanning Electron Microscopy (FE-SEM), and both nanofibers with (βG-nanofibers) or without βG (NoβG-nanofibers) were evaluated by their swelling index and FT-IR spectroscopy. The formulations, active ingredient and excipients were tested for their possible in vitro toxicity in keratinocytes. Fin...
European Journal of Pharmaceutical Sciences, 2017
Chronic wounds represent a significant health problem worldwide. There is a need for advancedand ... more Chronic wounds represent a significant health problem worldwide. There is a need for advancedand cost-efficient wound healing products able to increase patient comfort and reduce the healing time. The aim of this study was to develop a sprayable hydrogel dressing with beta-glucan (βG) as the active ingredient, targeting future application in the treatment of both chronic and burn wounds. The βG was chosen as an active ingredient because of its promising wound healing capabilities, whereas Carbopol 971P NF (Carbopol) was chosen as the thickening agent in the formulation due to several attractive characteristics such as its low viscosity, low toxicity, high transparency and good ion tolerance. Four different hydrogel formulations were prepared with varying Carbopol concentrations. The higher Carbopol concentration, 0.5 % (w/w), was used to prepare three formulations comprising the HighCP:NoβG, HighCP:LowβG and the HighCP:MediumβG formulation, respectively. Lower Carbopol concentration, 0.25 % (w/w), was used to prepare the LowCP:HighβG formulation. The content of βG varied from 0.25 % in the HighCP:LowβG, 0.5 % in the HighCP:MediumβG and 1.0 % (w/w) in the LowCP:HighβG formulation, respectively. The first part of the study focused on the rheological characterization of the hydrogels and the fluid affinity testing. All formulations were confirmed to be stable gels; the βG was shown to augment the gel strength by increasing the yield strength of the gel in a dose dependent manner. The stability of the formulations containing either Carbopol alone or in a combination with βG did not deteriorate over 26 weeks, and the fluid donation and absorption study indicated a fluid donation profile, which favors healing of dry wounds. The in vivo efficacy of the formulations, evaluated in the modified diabetic male mice (db/db mice), showed that Carbopol alone was unable to induce improved healing and caused adverse reactions in some wounds. The inclusion of βG increased the epithelialization and wound contraction in the db/db mice when given at high βG:Carbopol ratio. The positive effect of βG was, however, not sufficient to counteract the adverse effect of Carbopol, thus a more suitable thickening agent should be investigated for further development of a sprayable wound care product.
Develop Comp Immunol, 1994
本発明は、（ａ）果実酸アルキルエステル０.１〜３０質量％、（ｂ）アニオン界面活性剤および／または非イオン界面活性剤および／またはカチオン界面活性剤および／または両性界面活性剤および／または両性イ... more 本発明は、（ａ）果実酸アルキルエステル０.１〜３０質量％、（ｂ）アニオン界面活性剤および／または非イオン界面活性剤および／またはカチオン界面活性剤および／または両性界面活性剤および／または両性イオン界面活性剤０.１〜９０質量％、並びに任意に（ｃ）脂肪アルコール０.１〜１０質量％を含有する調剤に関する。 本発明は、果実酸アルキルエステルの界面活性配合物中における過脂肪剤としての使用にも関する。
Cette invention concerne l'utilisation de β-(1,3)-glucanes solubles dans l'eau, pratiquem... more Cette invention concerne l'utilisation de β-(1,3)-glucanes solubles dans l'eau, pratiquement exempts de liaisons (1,6), comme agents actifs pour la preparation d'agents therapeutiques pour les soins de peau. Lesdits agents therapeutiques renforcent le systeme immunitaire de la peau, agissent contre la formation des rides et peuvent etre utilises pour lutter contre les pellicules et le psoriasis.
b-Glucans are known for their ability to trigger both protective and damaging immune responses. H... more b-Glucans are known for their ability to trigger both protective and damaging immune responses. Here we have explored the role of the betaglucan receptor Dectin-1 in archetypical models of protective and non-protective immunomodulation induced by beta-glucan rich ligands. In the first model, we explored the role of Dectin-1 in the ability of soluble purified b-glucans to mediate protection against systemic Staphylococcus aureus infection in mice. In the second model, we explored the role of Dectin-1 in zymosan induced multiple organ dysfunction syndrome. In both cases, these b-glucan rich compounds had marked effects in vivo which were unaltered by Dectin-1 deficiency, suggesting that this receptor has a redundant role in these murine models. 2013 Institut Pasteur. Published by Elsevier Masson SAS.
TREATMENT TO BE - (1-6) -glucanase, glycan FROM YEAST CELLS, PARTICULARLY YEAST SACCHAROMYCES FAM... more TREATMENT TO BE - (1-6) -glucanase, glycan FROM YEAST CELLS, PARTICULARLY YEAST SACCHAROMYCES FAMILY AND ESPECIALLY of Saccharomyces cerevisiae, PROVIDES A NEW PRODUCT glucan, SUITABLE FOR USE IN ENHANCING STIMULATION immune systems of the host animal. Further it described solubilization OF SUCH glucan yeast cell, TO EXTEND THEIR USE AS AUXILIARY PRODUCT.
European Journal of Pharmaceutics and Biopharmaceutics, 2021
To relieve the severe economic and social burdens and patient suffering caused by the increasing ... more To relieve the severe economic and social burdens and patient suffering caused by the increasing incidence of chronic wounds, more effective treatments are urgently needed. In this study, we focused on developing a novel sprayable wound dressing with the active ingredient β-1,3/1,6-glucan (βG). Since βG is already available as the active ingredient in a commercial wound healing product provided as a hydrogel in a tube (βG-Gel), the sprayable format should bring clinical benefit by being easily sprayed onto wounds; whilst retaining βG-Gel's physical stability, biological safety and wound healing efficacy. Potentially sprayable βG hydrogels were therefore formulated, based on an experimental design setup. One spray formulation, named βG-Spray, was selected for further investigation, as it showed favorable rheological and spraying properties. The βG-Spray was furthermore found to be stable at room temperature for more than a year, retaining its rheological properties and sprayability. The cytotoxicity of βG-Spray in keratinocytes in vitro, was shown to be promising even at the highest tested concentration of 100 μg/ml. The βG-Spray also displayed favorable fluid affinity characteristics, with a capacity to both donate and absorb close to 10% fluid relative to its own weight. Finally, the βG-Spray was proven comparably effective to the commercial product, βG-Gel, and superior to both the water and the carrier controls (NoβG-Spray), in terms of its ability to promote wound healing in healing-impaired animals. Contraction was found to be the main wound closure mechanism responsible for the improvement seen in the βG-treatment groups (βG-Spray and βG-Gel). In conclusion, the novel sprayable βG formulation, confirmed its potential to expand the clinical use of βG as wound dressing.
Pharmaceutics, 2021
An active wound dressing should address the main goals in wound treatment, which are improved wou... more An active wound dressing should address the main goals in wound treatment, which are improved wound healing and reduced infection rates. We developed novel multifunctional nanofibrous wound dressings with three active ingredients: chloramphenicol (CAM), beta-glucan (βG) and chitosan (CHI), of which βG and CHI are active nanofiber-forming biopolymers isolated from the cell walls of Saccharomyces cerevisiae and from shrimp shells, respectively. To evaluate the effect of each active ingredient on the nanofibers’ morphological features and bioactivity, nanofibers with both βG and CHI, only βG, only CHI and only copolymers, polyethylene oxide (PEO) and hydroxypropylmethylcellulose (HPMC) were fabricated. All four nanofiber formulations were also prepared with 1% CAM. The needle-free NanospiderTM technique allowed for the successful production of defect-free nanofibers containing all three active ingredients. The CAM-containing nanofibers had a burst CAM-release and a high absorption capa...
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2018
The increased prevalence of chronic wounds requires novel treatment options. The aim of this stud... more The increased prevalence of chronic wounds requires novel treatment options. The aim of this study was to develop a beta-glucan (βG)-loaded nanofiber wound dressing. Nanofibers were prepared using the needle-free Nanospider™ technology, an electrospinning method which enables the production of nanofibers at an industrial scale. The βG was selected as active ingredient based on its confirmed wound healing potential in both animals and humans. Hydroxypropyl methylcellulose (HPMC) and polyethylene oxide (PEO) were included as copolymers. Rheological profiles of spinning solutions containing HPMC, PEO, βG, ethanol and water, were optimized. The nanofiber formation was confirmed by Field Emission Scanning Electron Microscopy (FE-SEM), and both nanofibers with (βG-nanofibers) or without βG (NoβG-nanofibers) were evaluated by their swelling index and FT-IR spectroscopy. The formulations, active ingredient and excipients were tested for their possible in vitro toxicity in keratinocytes. Fin...
European Journal of Pharmaceutical Sciences, 2017
Chronic wounds represent a significant health problem worldwide. There is a need for advancedand ... more Chronic wounds represent a significant health problem worldwide. There is a need for advancedand cost-efficient wound healing products able to increase patient comfort and reduce the healing time. The aim of this study was to develop a sprayable hydrogel dressing with beta-glucan (βG) as the active ingredient, targeting future application in the treatment of both chronic and burn wounds. The βG was chosen as an active ingredient because of its promising wound healing capabilities, whereas Carbopol 971P NF (Carbopol) was chosen as the thickening agent in the formulation due to several attractive characteristics such as its low viscosity, low toxicity, high transparency and good ion tolerance. Four different hydrogel formulations were prepared with varying Carbopol concentrations. The higher Carbopol concentration, 0.5 % (w/w), was used to prepare three formulations comprising the HighCP:NoβG, HighCP:LowβG and the HighCP:MediumβG formulation, respectively. Lower Carbopol concentration, 0.25 % (w/w), was used to prepare the LowCP:HighβG formulation. The content of βG varied from 0.25 % in the HighCP:LowβG, 0.5 % in the HighCP:MediumβG and 1.0 % (w/w) in the LowCP:HighβG formulation, respectively. The first part of the study focused on the rheological characterization of the hydrogels and the fluid affinity testing. All formulations were confirmed to be stable gels; the βG was shown to augment the gel strength by increasing the yield strength of the gel in a dose dependent manner. The stability of the formulations containing either Carbopol alone or in a combination with βG did not deteriorate over 26 weeks, and the fluid donation and absorption study indicated a fluid donation profile, which favors healing of dry wounds. The in vivo efficacy of the formulations, evaluated in the modified diabetic male mice (db/db mice), showed that Carbopol alone was unable to induce improved healing and caused adverse reactions in some wounds. The inclusion of βG increased the epithelialization and wound contraction in the db/db mice when given at high βG:Carbopol ratio. The positive effect of βG was, however, not sufficient to counteract the adverse effect of Carbopol, thus a more suitable thickening agent should be investigated for further development of a sprayable wound care product.
Develop Comp Immunol, 1994
本発明は、（ａ）果実酸アルキルエステル０.１〜３０質量％、（ｂ）アニオン界面活性剤および／または非イオン界面活性剤および／またはカチオン界面活性剤および／または両性界面活性剤および／または両性イ... more 本発明は、（ａ）果実酸アルキルエステル０.１〜３０質量％、（ｂ）アニオン界面活性剤および／または非イオン界面活性剤および／またはカチオン界面活性剤および／または両性界面活性剤および／または両性イオン界面活性剤０.１〜９０質量％、並びに任意に（ｃ）脂肪アルコール０.１〜１０質量％を含有する調剤に関する。 本発明は、果実酸アルキルエステルの界面活性配合物中における過脂肪剤としての使用にも関する。